Cargando…

Treatment Outcomes of Pulpotomy with Propolis in Comparison with MTA in Human Primary Molars: A 24-month Follow-up Randomized Controlled Trial

AIM AND OBJECTIVE: To evaluate the clinical efficacy of propolis as pulpotomy medicament in human primary molars. MATERIALS AND METHODS: This randomized controlled trial is a two-arm, parallel group study with blinded outcome assessment. The study included a total of 60 primary molars that require p...

Descripción completa

Detalles Bibliográficos
Autores principales: RojaRamya, Kakarla Sri, Chandrasekhar, Rayala, Uloopi, KS, Vinay, C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Jaypee Brothers Medical Publishers 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9108812/
https://www.ncbi.nlm.nih.gov/pubmed/35645503
http://dx.doi.org/10.5005/jp-journals-10005-2120
_version_ 1784708786288590848
author RojaRamya, Kakarla Sri
Chandrasekhar, Rayala
Uloopi, KS
Vinay, C
author_facet RojaRamya, Kakarla Sri
Chandrasekhar, Rayala
Uloopi, KS
Vinay, C
author_sort RojaRamya, Kakarla Sri
collection PubMed
description AIM AND OBJECTIVE: To evaluate the clinical efficacy of propolis as pulpotomy medicament in human primary molars. MATERIALS AND METHODS: This randomized controlled trial is a two-arm, parallel group study with blinded outcome assessment. The study included a total of 60 primary molars that require pulpotomy treatment in 4- 8-year old children. Teeth were assigned to two groups randomly: Propolis (Test group); Mineral trioxide aggregate (MTA) (Control group). All the pulpotomized teeth were given stainless steel crowns and the teeth were evaluated clinically and radiographically at 6, 12, and 24 months to grade them as either success or failure. Chi-square test was employed to analyze the data. RESULTS: Success rates of pulpotomy with propolis and MTA were 80% and 93.1% respectively at 24 months of follow-up interval. Propolis has shown success rates of 90% and 80% at 6- and 12-month follow-up, while MTA has shown a consistent success rate of 93.1% at all the follow-up intervals. The difference in success rate between the groups at all the time intervals is statistically nonsignificant. CONCLUSION: Propolis has demonstrated a clinically acceptable success rate comparable to MTA as pulpotomy medicament in primary teeth. CLINICAL SIGNIFICANCE: Biocompatible materials with regenerative potential have drawn the momentum in vital pulp therapy. In this regard, MTA has been emerged as most successful material, but its high cost has limited its use. Hence, there is an absolute need of cost-effective pulpotomy material with regenerative potential. This study provides an evidence that propolis has clinically acceptable success rate as pulpotomy medicament. Considering its low cost and ready availability, it can be recommended as a cost-effective alternative for primary teeth pulpotomy. HOW TO CITE THIS ARTICLE: RojaRamya KS, Chandrasekhar R, Uloopi KS, et al. Treatment Outcomes of Pulpotomy with Propolis in Comparison with MTA in Human Primary Molars: A 24-month Follow-up Randomized Controlled Trial. Int J Clin Pediatr Dent 2022;15(S-1):S3-S7.
format Online
Article
Text
id pubmed-9108812
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Jaypee Brothers Medical Publishers
record_format MEDLINE/PubMed
spelling pubmed-91088122022-05-27 Treatment Outcomes of Pulpotomy with Propolis in Comparison with MTA in Human Primary Molars: A 24-month Follow-up Randomized Controlled Trial RojaRamya, Kakarla Sri Chandrasekhar, Rayala Uloopi, KS Vinay, C Int J Clin Pediatr Dent Research Article AIM AND OBJECTIVE: To evaluate the clinical efficacy of propolis as pulpotomy medicament in human primary molars. MATERIALS AND METHODS: This randomized controlled trial is a two-arm, parallel group study with blinded outcome assessment. The study included a total of 60 primary molars that require pulpotomy treatment in 4- 8-year old children. Teeth were assigned to two groups randomly: Propolis (Test group); Mineral trioxide aggregate (MTA) (Control group). All the pulpotomized teeth were given stainless steel crowns and the teeth were evaluated clinically and radiographically at 6, 12, and 24 months to grade them as either success or failure. Chi-square test was employed to analyze the data. RESULTS: Success rates of pulpotomy with propolis and MTA were 80% and 93.1% respectively at 24 months of follow-up interval. Propolis has shown success rates of 90% and 80% at 6- and 12-month follow-up, while MTA has shown a consistent success rate of 93.1% at all the follow-up intervals. The difference in success rate between the groups at all the time intervals is statistically nonsignificant. CONCLUSION: Propolis has demonstrated a clinically acceptable success rate comparable to MTA as pulpotomy medicament in primary teeth. CLINICAL SIGNIFICANCE: Biocompatible materials with regenerative potential have drawn the momentum in vital pulp therapy. In this regard, MTA has been emerged as most successful material, but its high cost has limited its use. Hence, there is an absolute need of cost-effective pulpotomy material with regenerative potential. This study provides an evidence that propolis has clinically acceptable success rate as pulpotomy medicament. Considering its low cost and ready availability, it can be recommended as a cost-effective alternative for primary teeth pulpotomy. HOW TO CITE THIS ARTICLE: RojaRamya KS, Chandrasekhar R, Uloopi KS, et al. Treatment Outcomes of Pulpotomy with Propolis in Comparison with MTA in Human Primary Molars: A 24-month Follow-up Randomized Controlled Trial. Int J Clin Pediatr Dent 2022;15(S-1):S3-S7. Jaypee Brothers Medical Publishers 2022 /pmc/articles/PMC9108812/ /pubmed/35645503 http://dx.doi.org/10.5005/jp-journals-10005-2120 Text en Copyright © 2022; The Author(s). https://creativecommons.org/licenses/by-nc/4.0/© The Author(s). 2022 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted use, distribution, and non-commercial reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
RojaRamya, Kakarla Sri
Chandrasekhar, Rayala
Uloopi, KS
Vinay, C
Treatment Outcomes of Pulpotomy with Propolis in Comparison with MTA in Human Primary Molars: A 24-month Follow-up Randomized Controlled Trial
title Treatment Outcomes of Pulpotomy with Propolis in Comparison with MTA in Human Primary Molars: A 24-month Follow-up Randomized Controlled Trial
title_full Treatment Outcomes of Pulpotomy with Propolis in Comparison with MTA in Human Primary Molars: A 24-month Follow-up Randomized Controlled Trial
title_fullStr Treatment Outcomes of Pulpotomy with Propolis in Comparison with MTA in Human Primary Molars: A 24-month Follow-up Randomized Controlled Trial
title_full_unstemmed Treatment Outcomes of Pulpotomy with Propolis in Comparison with MTA in Human Primary Molars: A 24-month Follow-up Randomized Controlled Trial
title_short Treatment Outcomes of Pulpotomy with Propolis in Comparison with MTA in Human Primary Molars: A 24-month Follow-up Randomized Controlled Trial
title_sort treatment outcomes of pulpotomy with propolis in comparison with mta in human primary molars: a 24-month follow-up randomized controlled trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9108812/
https://www.ncbi.nlm.nih.gov/pubmed/35645503
http://dx.doi.org/10.5005/jp-journals-10005-2120
work_keys_str_mv AT rojaramyakakarlasri treatmentoutcomesofpulpotomywithpropolisincomparisonwithmtainhumanprimarymolarsa24monthfollowuprandomizedcontrolledtrial
AT chandrasekharrayala treatmentoutcomesofpulpotomywithpropolisincomparisonwithmtainhumanprimarymolarsa24monthfollowuprandomizedcontrolledtrial
AT uloopiks treatmentoutcomesofpulpotomywithpropolisincomparisonwithmtainhumanprimarymolarsa24monthfollowuprandomizedcontrolledtrial
AT vinayc treatmentoutcomesofpulpotomywithpropolisincomparisonwithmtainhumanprimarymolarsa24monthfollowuprandomizedcontrolledtrial